Press Releases Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
5.560 ^USD	+14.88%		+30.82%	+152.73%

Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI
Nov. 07	Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Press Releases

Immix Biopharma : Presentation (IMMX Corporate presentation – November 2025)	Dec. 02	PU
Immix Biopharma : Presentation (IMMX Corporate presentation – December 2024)	Dec. 02	PU
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch	Nov. 12	GL
Immix Biopharma : Presentation (IMMX Corporate presentation November 2025)	Nov. 03	PU
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025	Nov. 03	GL
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference	Oct. 14	GL
Immix Biopharma : Presentation (IMMX Corporate presentation October 2025)	Oct. 08	PU
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting	Oct. 06	GL
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference	Oct. 01	GL
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2	Sep. 18	GL
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors	Sep. 11	GL
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang	Sep. 08	GL
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang	Sep. 08	AQ
Immix Biopharma : Presentation (IMMX Corporate presentation September 2025)	Sep. 02	PU
Immix Biopharma : Presentation (IMMX Corporate presentation August 2025 1)	Aug. 26	PU
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference	Aug. 25	GL
Immix Biopharma : Presentation (IMMX Corporate presentation August 2025)	Aug. 07	PU
Immix Biopharma Announces Other Serious Diseases Strategy	Aug. 06	GL
Immix Biopharma : Presentation (IMMX Corporate presentation July 2025)	Jul. 14	PU
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion	Jul. 11	GL
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis	Jul. 07	GL
Immix Biopharma Attends FDA CEO Forum in Washington DC	Jun. 06	GL
Immix Biopharma : Presentation (IMMX Corporate presentation June 2025)	Jun. 04	PU
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis	Jun. 03	GL
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis	Jun. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Biotechnology & Medical Research

Press Releases

Filters